Pharmacologic Options for the Treatment of Sarcopenia
The DOI matches its Crossref record; 161 of the 161 references it cites were found in a registry or an index.
Abstract
Sarcopenia is now clinically defined as a loss of muscle mass coupled with functional deterioration (either walking speed or distance or grip strength). Based on the FRAX studies suggesting that the questions without bone mineral density can be used to screen for osteoporosis, there is now a valid simple questionnaire to screen for sarcopenia, i.e., the SARC-F. Numerous factors have been implicated in the pathophysiology of sarcopenia. These include genetic factors, mitochondrial defects, decreased anabolic hormones (e.g., testosterone, vitamin D, growth hormone and insulin growth hormone-1), inflammatory cytokine excess, insulin resistance, decreased protein intake and activity, poor blood flow to muscle and deficiency of growth derived factor-11. Over the last decade, there has been a remarkable increase in our understanding of the molecular biology of muscle, resulting in a marked increase in potential future targets for the treatment of sarcopenia. At present, resistance exercise, protein supplementation, and vitamin D have been established as the basic treatment of sarcopenia. High-dose testosterone increases muscle power and function, but has a number of potentially limiting side effects. Other drugs in clinical development include selective androgen receptor molecules, ghrelin agonists, myostatin antibodies, activin IIR antagonists, angiotensin converting enzyme inhibitors, beta antagonists, and fast skeletal muscle troponin activators. As sarcopenia is a major predictor of frailty, hip fracture, disability, and mortality in older persons, the development of drugs to treat it is eagerly awaited.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Multiple pathways are involved in the loss of muscle mass arising from aging, malnutrition, obesity, inflammation and inactivity, which offers many targets for therapeutic intervention [102].”
From Is There Enough Evidence for Osteosarcopenic Obesity as a Distinct Entity? A Critical Literature Review (2019) · cites this paper as [102]
In the citing paper
“Multiple pathways are involved in the loss of muscle mass arising from aging, malnutrition, obesity, inflammation and inactivity, which offers many targets for therapeutic intervention [102].”
From Is There Enough Evidence for Osteosarcopenic Obesity as a Distinct Entity? A Critical Literature Review (2019) · cites this paper as [102]
Citations
Cites
Sarcopenia: European consensus on definition and diagnosis
Cruz-Jentoft, A. J., Baeyens, J. P., Bauer, J. M., Boirie, Y., Cederholm, T., Landi, F., Martin, F. C., Michel, J.-P., Rolland, Y., Schneider, S. M., et al. (2010) · Age and Ageing · doi:10.1093/ageing/afq034 · Cited by 11,601
Sarcopenia in Asia: Consensus Report of the Asian Working Group for Sarcopenia
Chen, L.-K., Liu, L.-K., Woo, J., Assantachai, P., Auyeung, T.-W., Bahyah, K. S., Chou, M.-Y., Chen, L.-Y., Hsu, P.-S., Krairit, O., et al. (2014) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2013.11.025 · Cited by 4,051
Frailty Consensus: A Call to Action
Morley, J. E., Vellas, B., Abellan van Kan, G., Anker, S. D., Bauer, J. M., Bernabei, R., Cesari, M., Chumlea, W. C., Doehner, W., Evans, J., et al. (2013) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2013.03.022 · Cited by 4,043 · cited 1×
“Fatigue is an important component of the frailty phenotype that is separate from sarcopenia [33, 34].”
BackgroundSelf-citationFielding, R. A., Vellas, B., Evans, W. J., Bhasin, S., Morley, J. E., Newman, A. B., Abellan van Kan, G., Andrieu, S., Bauer, J., Breuille, D., et al. (2011) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2011.01.003 · Cited by 3,256
Self-citationBauer, J., Biolo, G., Cederholm, T., Cesari, M., Cruz-Jentoft, A. J., Morley, J. E., Phillips, S., Sieber, C., Stehle, P., Teta, D., et al. (2013) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2013.05.021 · Cited by 2,553
Self-citationRejuvenation of aged progenitor cells by exposure to a young systemic environment
Conboy, I. M., Conboy, M. J., Wagers, A. J., Girma, E. R., Weissman, I. L., & Rando, T. A. (2005) · Nature · doi:10.1038/nature03260 · Cited by 2,287 · cited 1×
“Studies with parabiotic mice have shown that the combination of a young and an old mouse leads to rejuvenation in the muscle of the older mouse [65].”
BackgroundEffects of Human Growth Hormone in Men over 60 Years Old
Rudman, D., Feller, A. G., Nagraj, H. S., Gergans, G. A., Lalitha, P. Y., Goldberg, A. F., Schlenker, R. A., Cohn, L., Rudman, I. W., & Mattson, D. E. (1990) · New England Journal of Medicine · doi:10.1056/nejm199007053230101 · Cited by 1,555
Pahor, M., Guralnik, J. M., Ambrosius, W. T., Blair, S., Bonds, D. E., Church, T. S., Espeland, M. A., Fielding, R. A., Gill, T. M., Groessl, E. J., et al. (2014) · JAMA · doi:10.1001/jama.2014.5616 · Cited by 1,427 · cited 1×
“As was shown by the LIFE study, aerobic exercise can also decrease functional decline in lower limb muscles [74].”
MethodMyostatin Mutation Associated with Gross Muscle Hypertrophy in a Child
Schuelke, M., Wagner, K. R., Stolz, L. E., Hübner, C., Riebel, T., Kömen, W., Braun, T., Tobin, J. F., & Lee, S.-J. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040933 · Cited by 1,399
SARC-F: A simple questionnaire to rapidly diagnose sarcopenia
Malmstrom, T. K., & Morley, J. E. (2013) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2013.05.018 · Cited by 1,319 · cited 1×
“without Bone Mineral Density are highly predictive of fracture risk [14], we developed a simple sarcopenic questionnaire to predict poor muscle function (Table 2) [15].”
BackgroundSelf-citation
Research works printed but not linked: 4
- Rolland Y, Lauwers-Cances V, Crostini C, Abellan van Kan G, Janssen I, Morley JE, Vellas B (2009) Difficulties with physical function associated with obesity, sarcopenia, and sarcopenic-obesity in community-dwelling elderly women. EPIDOS Study 89:1895–1900
- Kim MJ, Morley JE (2005) The hormonal fountains of youth: myth or reality? J Endocrinol Invest 28(11):5–14
- Temel J, Bondarde S, Jain M, Yun Y, Duus E, Allen S et al (2013) Efficacy and safety results from a phase II study of anamorelin HC21, a ghrelin receptor agonist, in NSCLC patients. J Cachexia Sarcopenia Muscle 4:334
- Malik F (2013) Fast skeletal muscle troponin activators and their application to disease-preclinical characterization. In: Abstracts, 7th Cachexia Conference, Kobe. p 50
Cited by
International exercise recommendations in older adults (ICFSR): Expert consensus guidelines
Izquierdo, M., Merchant, R. A., Morley, J. E., Anker, S. D., Aprahamian, I., Arai, H., Aubertin-Leheudre, M., Bernabei, R., Cadore, E. L., Cesari, M., et al. (2021) · The Journal of nutrition, health and aging · doi:10.1007/s12603-021-1665-8 · Cited by 1,247
Self-citationDent, E., Morley, J. E., Cruz-Jentoft, A. J., Arai, H., Kritchevsky, S. B., Guralnik, J., Bauer, J. M., Pahor, M., Clark, B. C., Cesari, M., et al. (2018) · The Journal of nutrition, health and aging · doi:10.1007/s12603-018-1139-9 · Cited by 1,130
Self-citationWelcome to the ICD‐10 code for sarcopenia
Anker, S. D., Morley, J. E., & von Haehling, S. (2016) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.12147 · Cited by 983
Self-citationSarcopenia: A Time for Action. An SCWD Position Paper
Bauer, J., Morley, J. E., Schols, A. M. W. J., Ferrucci, L., Cruz‐Jentoft, A. J., Dent, E., Baracos, V. E., Crawford, J. A., Doehner, W., Heymsfield, S. B., et al. (2019) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.12483 · Cited by 734
Self-citationSkeletal Muscle Regulates Metabolism via Interorgan Crosstalk: Roles in Health and Disease
Argilés, J. M., Campos, N., Lopez-Pedrosa, J. M., Rueda, R., & Rodriguez-Mañas, L. (2016) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2016.04.019 · Cited by 581
Metadata
- Authors
- Morley, J. E.
- Affiliations
- Saint Louis University (US)
- Corresponding author
- Morley, John E.
- ORCID
- Morley, John E.
- Venue
- Calcified Tissue International
- Published
- 2015-06-23
- Volume
- 98
- Issue
- 4
- Pages
- 319-333
- ISSN
- 0171-967X (ISSN-L)
- 1432-0827
- OpenAlex
- W819537267
- Cited by
- 225
- References
- 161
- Citations by year
- 2026: 10 · 2025: 18 · 2024: 16 · 2023: 15 · 2022: 20 · 2021: 23 · 2020: 20 · 2019: 23 · 2018: 29 · 2017: 27 · 2016: 18 · 2015: 6
- FWCI
- 3.27
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Calcified Tissue International (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Physiology (medical) › Nutrition and Health in Aging
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Keywords
- sarcopenia, sarcopenia treatment, muscle mass loss, muscle function, testosterone replacement therapy, selective androgen receptor modulators, ghrelin agonists, ACE inhibitors, beta-blockers, protein supplementation, vitamin D, resistance training, frailty, older adults
- MeSH terms
- Humans, Drug Discovery, Sarcopenia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacologic Options for the Treatment of Sarcopenia. https://app.cochat.ai/papers/10.1007/s00223-015-0022-5
- The paper
- Morley, J. E. (2016). Pharmacologic Options for the Treatment of Sarcopenia. Calcified Tissue International. https://doi.org/10.1007/s00223-015-0022-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.